Philip J. Stephens

77.2k citations

346 papers · 41.0k indexed · 9 hit papers · h-index 77

Impact in

Spectroscopy top 0.01%
- Molecular spectroscopy and chirality
- Analytical Chemistry and Chromatography
Physical and Theoretical Chemistry top 0.05%
- Photochemistry and Electron Transfer Studies

Papers in

Spectroscopy 101
- Molecular spectroscopy and chirality 96
- Analytical Chemistry and Chromatography 19
Cancer Research 90
- Cancer Genomics and Diagnostics 84

Co-authors: F. J. Devlin Michael J. Frisch Cary F. Chabalowski James R. Cheeseman Vincent A. Miller Jeffrey S. Ross Siraj M. Ali Garrett M. Frampton
Journals: Journal of Clinical Oncology (46 papers)Journal of the American Chemical Society (17 papers)Cancer Research (15 papers)The Journal of Physical Chemistry (13 papers)The Journal of Organic Chemistry (13 papers)
Partner nations: United States Italy United Kingdom

In The Last Decade

Philip J. Stephens

343 papers receiving 40.3k citations

Hit Papers

9 papers align trajectories log scale

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study 2019 · 429 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 Nature Medicine
2017 Molecular Cancer Therapeutics
2015 Cancer Discovery
2009 Chirality
2008 Nature Methods
2002 The Journal of Physical Chemistry A
1996 Chemical Reviews
1994 The Journal of Physical Chemistry
1985 The Journal of Physical Chemistry

Peers

Countries citing papers authored by Philip J. Stephens

Since Specialization

Citations

This map shows the geographic impact of Philip J. Stephens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip J. Stephens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip J. Stephens more than expected).

Fields of papers citing papers by Philip J. Stephens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip J. Stephens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip J. Stephens. The network helps show where Philip J. Stephens may publish in the future.

Co-authors

The 25 scholars most cited alongside Philip J. Stephens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Philip J. Stephens Line = papers co-authored together Philip J. Stephens links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus Clinical Cancer Research ·Alexa B. Schrock, Dean C. Pavlick, Samuel J. Klempner, Jon Chung, Brady Forcier, Allison W. Welsh, Lauren Young, B Leyland-Jones, Rodolfo Bordoni, Richard D. Carvajal, Joseph Chao, Razelle Kurzrock, Jason K. Sicklick, Jeffrey S. Ross, Philip J. Stephens, Craig Devoe, Fadi Braiteh, Siraj M. Ali, Vincent A. Miller	2018	54
2	Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3 Cancer ·Jeffrey S. Ross, Marwan Fakih, Siraj M. Ali, Julia A. Elvin, Alexa B. Schrock, James Suh, Jo‐Anne Vergilio, Shakti Ramkissoon, Eric A. Severson, Sugganth Daniel, David Fabrizio, Garrett M. Frampton, James Sun, Vincent A. Miller, Philip J. Stephens, Laurie M. Gay	2018	149
3	Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC PLoS ONE ·Michael E. Goldberg, Meagan Montesion, Lauren Young, James Suh, Joel Greenbowe, Mark Kennedy, Giuseppe Giaccone, Wallace Akerley, Afshin Dowlati, Ben Creelan, J. Kevin Hicks, Paul J. Hesketh, Karen Kelly, Jonathan W. Riess, Vincent A. Miller, Philip J. Stephens, Garrett M. Frampton, Siraj M. Ali, Jeffrey P. Gregg, Lee A. Albacker	2018	15
4	High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis Cancer Research ·Ryan J. Hartmaier, Lee A. Albacker, Juliann Chmielecki, Mark Bailey, Jie He, Michael E. Goldberg, Shakti Ramkissoon, James Suh, Julia A. Elvin, Samuel Chiacchia, Garrett M. Frampton, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens, Doron Lipson	2017	85
5	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers Molecular Cancer Therapeutics ·Aaron M. Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip Pravin Patel, Garrett M. Frampton, Vincent A. Miller, Philip J. Stephens, Gregory A. Daniels, Razelle Kurzrock Hit paper breakdown →	2017	1638
6	BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy Pigment Cell & Melanoma Research ·Douglas B. Johnson, Merrida Childress, Zachary R. Chalmers, Garrett M. Frampton, Siraj M. Ali, Samuel M. Rubinstein, David Fabrizio, Jeffrey S. Ross, Sohail Balasubramanian, Vincent A. Miller, Philip J. Stephens, Jeffrey A. Sosman, Christine M. Lovly	2017	28
7	Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy Cancer ·Siraj M. Ali, Ming Yao, Jicheng Yao, Jing Wang, Yu‐Wei Cheng, Alexa B. Schrock, Gung‐Wei Chirn, Hui Chen, Shuo Mu, Laurie M. Gay, Julia A. Elvin, James Suh, Vincent A. Miller, Philip J. Stephens, Jeffrey S. Ross, Kai Wang	2017	36
8	Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target Clinical Cancer Research ·Evgeny Yakirevich, Murray B. Resnick, Shamlal Mangray, Michael B. Wheeler, Cynthia L. Jackson, Kara A. Lombardo, Jeeyun Lee, Kyoung‐Mee Kim, Anthony J. Gill, Kai Wang, Kyle Gowen, James Sun, Vincent A. Miller, Philip J. Stephens, Siraj M. Ali, Jeffrey S. Ross, Howard Safran	2016	88
9	Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation Clinical Cancer Research ·Jamie M. Sperger, Lindsay N. Strotman, Allison W. Welsh, Benjamin P. Casavant, Zachery Chalmers, Sacha Horn, Erika Héninger, Stephanie M. Thiede, Jacob Tokar, Benjamin K. Gibbs, David J. Guckenberger, Lakeesha Carmichael, Scott M. Dehm, Philip J. Stephens, David J. Beebe, Scott M. Berry, Joshua M. Lang	2016	50
10	An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101 Cancer Discovery ·Robert C. Doebele, Lara E. Davis, Aria Vaishnavi, Anh T. Le, Adriana Estrada‐Bernal, Stephen B. Keysar, Antonio Jimeno, Marileila Varella‐Garcia, Dara L. Aisner, Yali Li, Philip J. Stephens, Deborah Morosini, Brian B. Tuch, Michele Fernandes, Nisha Nanda, Jennifer A. Low Hit paper breakdown →	2015	302
11	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences The Oncologist ·Kai Wang, Adrienne Johnson, Siraj M. Ali, Samuel J. Klempner, Tanios Bekaii‐Saab, Jeffrey Vacirca, Depinder Khaira, Roman Yelensky, Juliann Chmielecki, Julia A. Elvin, Doron Lipson, Vincent A. Miller, Philip J. Stephens, Jeffrey S. Ross	2015	75
12	Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions Cancer Discovery ·Christine M. Lovly, Abha A. Gupta, Doron Lipson, Geoff Otto, Tina Brennan, Catherine T. Chung, Scott C. Borinstein, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Cheryl M. Coffin	2014	303
13	Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer Molecular Cancer Therapeutics ·Funda Meric‐Bernstam, Garrett M. Frampton, Jaime Ferrer-Lozano, Roman Yelensky, José Alejandro Pérez Fidalgo, Ying Wang, Gary A. Palmer, Jeffrey S. Ross, Vincent A. Miller, Xiaoping Su, Pîlar Eroles, Juan Antonio Barrera, Octavio Burgués, Aňa Lluch, Xiaofeng Zheng, Ayşegül Şahin, Philip J. Stephens, Gordon B. Mills, Maureen Cronin, Ana M. González-Angulo	2014	68
14	Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes Cancer Discovery ·Juliann Chmielecki, Katherine E. Hutchinson, Garrett M. Frampton, Zachary R. Chalmers, Adrienne Johnson, Chanjuan Shi, Julia A. Elvin, Siraj M. Ali, Jeffrey S. Ross, Olca Baştürk, Sohail Balasubramanian, Doron Lipson, Roman Yelensky, William Pao, Vincent A. Miller, David S. Klimstra, Philip J. Stephens	2014	126
15	Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted Therapy Journal of Clinical Oncology ·Siraj M. Ali, R. Katherine Alpaugh, Sean R. Downing, Philip J. Stephens, Jian Yu, Hong Wu, Jamie Buell, Vincent A. Miller, Doron Lipson, Gary A. Palmer, Jeffrey S. Ross, Massimo Cristofanilli	2014	40
16	BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition Clinical Cancer Research ·Katherine E. Hutchinson, Doron Lipson, Philip J. Stephens, Geoff Otto, Brian D. Lehmann, Pamela L. Lyle, Cindy L. Vnencak‐Jones, Jeffrey S. Ross, Jennifer A. Pietenpol, Jeffrey A. Sosman, Igor Puzanov, Vincent A. Miller, William Pao	2013	124
17	Novel Chromosomal Rearrangements and Break Points at the t(6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB – NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome Clinical Cancer Research ·Yoshitsugu Mitani, Pulivarthi H. Rao, P. Andrew Futreal, Dianna Roberts, Philip J. Stephens, Yi-Jue Zhao, Li Zhang, Mutsumi Mitani, Randal S. Weber, Scott M. Lippman, Carlos Caulı́n, Adel K. El‐Naggar	2011	116
18	Efficient Thia‐Bridged Triarylamine Heterohelicenes: Synthesis, Resolution, and Absolute Configuration Determination Chemistry - A European Journal ·Giuseppe Lamanna, Cristina Faggi, Francesco Gasparrini, Alessia Ciogli, Claudio Villani, Philip J. Stephens, F. J. Devlin, Stefano Menichetti	2008	59
19	Vibrational Circular Dichroism Spectroscopy: A New Tool for the Sterochemical Characterization of Chiral Molecules ChemInform ·Philip J. Stephens	2003	7
20	Ethanol decreases the velocity of spike propagation along a fast motor axon Alcohol ·Philip J. Stephens	1992	1

About Philip J. Stephens

Philip J. Stephens is a scholar working on Spectroscopy, Cancer Research, Oncology, Atomic and Molecular Physics, and Optics and Pulmonary and Respiratory Medicine, having authored 346 papers that have together received 41.0k indexed citations. Recurring topics across this work include Molecular spectroscopy and chirality (96 papers), Cancer Genomics and Diagnostics (84 papers), Spectroscopy and Quantum Chemical Studies (73 papers), Lung Cancer Treatments and Mutations (44 papers), Genetic factors in colorectal cancer (25 papers), Neurobiology and Insect Physiology Research (22 papers), Axial and Atropisomeric Chirality Synthesis (22 papers) and Analytical Chemistry and Chromatography (19 papers). The work is most often cited by research in Spectroscopy (8.5k citations), Physical and Theoretical Chemistry (3.6k citations), Organic Chemistry (9.9k citations), Inorganic Chemistry (4.6k citations) and Atomic and Molecular Physics, and Optics (9.1k citations). Philip J. Stephens has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include F. J. Devlin, Michael J. Frisch, Cary F. Chabalowski, James R. Cheeseman, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali, Garrett M. Frampton, Nobuyuki Harada and Doron Lipson. Their work appears in journals such as Journal of Clinical Oncology, Journal of the American Chemical Society, Cancer Research, The Journal of Physical Chemistry and The Journal of Organic Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact